S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

GLMD Galmed Pharmaceuticals Ltd

2.80

-0.13 (-4.44%)

Jan 17 2025 - Closed

Delayed by 15 minutes

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Galmed Pharmaceuticals Charts.

Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Galmed Pharmaceuticals Charts.

Galmed Pharmaceuticals Ltd. News

Form S-8 - Securities to be offered to employees in employee benefit plans
Tuesday 7 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Thursday 21 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form F-3 - Registration statement by foreign private issuers
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Monday 28 October 2024 (3 months ago) • Edgar (US Regulatory)

Form F-1 - Registration statement for certain foreign private issuers
Monday 21 October 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 21 October 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 15 October 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 25 September 2024 (4 months ago) • Edgar (US Regulatory)

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Wednesday 25 September 2024 (4 months ago) • PR Newswire (US)

More Galmed Pharmaceuticals Ltd. News Articles

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions